Q2 2025 GoodRx Holdings Inc Earnings Call Transcript
Key Points
- GoodRx Holdings Inc (GDRX) reported a 32% year-over-year revenue growth in its pharma manufacturer solutions, driven by strengthened relationships with pharma manufacturers and increased monetization per brand.
- The company has expanded its integrated savings program to include brand medications in addition to generics, enhancing its value proposition.
- GoodRx Holdings Inc (GDRX) launched new e-commerce solutions with additional retailers and is in contract discussions with several more, indicating potential future growth.
- The company introduced a new subscription product for erectile dysfunction, which has shown promising early results, with plans to expand into weight loss and hair loss treatments.
- GoodRx Holdings Inc (GDRX) maintained a strong adjusted EBITDA margin of 34.2%, an improvement of 160 basis points over the same period last year, demonstrating operational efficiency.
- The bankruptcy of Rite Aid and the decline in volume of one of GoodRx Holdings Inc (GDRX)'s integrated savings programs with a PBM partner negatively impacted revenue, contributing to a 3% decline in prescription transaction revenue.
- The company expects monthly active consumers to decline in the short term, partly due to the transition from traditional retail counter transactions to consumer direct price points.
- GoodRx Holdings Inc (GDRX) lowered its revenue projections for 2025 due to external factors, including the Rite Aid bankruptcy and ISP program erosion, resulting in an expected revenue loss of approximately $35 to $40 million.
- The company's gold subscription service saw a decline, although it is being offset by new subscription offerings.
- GoodRx Holdings Inc (GDRX) faces challenges in recapturing displaced consumers from Rite Aid closures, which may take time to resolve.
Hello and welcome to GoodRX Second quarter 2025 conference call and webcast. (Operator Instructions)
I would now like to turn the conference over to Aubrey Reynolds. You may begin.
Welcome to GX's earnings conference call for the 2nd quarter 2025. Joining me today are Wendy Barnes, our Chief Executive Officer, and chief Chris Mingus, our Chief Financial Officer.
Before we begin, I'd like to remind everyone that this call will contain forward-looking statements.
All statements made on this call that do not relate to matters of historical fact, should be considered forward-looking statements.
Including without limitations, statements regarding management plans, strategies, goals and objectives, or market opportunity, or financial, anticipated financial performance, underlying underlying trends in our business and industry, including ongoing changes in the pharmacy ecosystem.
Our value proposition, our long term growth prospects, our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
